The United Kingdom and the United States have agreed to a important trade agreement that will guarantee no import taxes on UK pharmaceutical products being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these key goods will stay at nothing for a timeframe of 36 months.
This deal follows earlier threats to significantly raise tariffs on branded drug imports, with increases discussed reaching double the cost.
"This agreement between the Britain bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a release noted.
Commercial Importance
Pharmaceuticals are one of the Britain's biggest export categories to the America, which is clearly the primary destination for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months prior to September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This amount represented a significant portion of all goods exports in that timeframe.
"This agreement protects jobs, stimulates funding and paves the way for the UK to emerge as a worldwide center for medical research," a government official remarked.
Specific NHS Changes
The pact involves several specific pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a aim to raise overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Previously, repayments were more than 20%.
Broader Context
The deal follows a protracted tension between the sector and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that American consumers were charged a premium for the identical medicines than people in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while substantial expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
